Accelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in healthcare sales in the third quarter, and a rise in its full-year ...

Roche's Ocrevus (ocrelizumab) is better at controlling disease activity in relapsing multiple sclerosis than German Merck's Rebif (interferon beta-1a), according to ...